NICE (Multiple) Technology Appraisal Guidance No 209 - Imatinib
for the treatment of unresectable and/or metastatic
gastrointestinal stromal tumours (part review of technology
appraisal guidance 86)
The following NICE appraisal, published today
24th November 2010, has been considered by NHS Quality
Improvement Scotland through its revised procedure of processing of
NICE appraisals
NICE (Multiple) Technology Appraisal Guidance No
209 –
Imatinib for the treatment of unresectable
and/or metastatic gastrointestinal stromal tumours (part review of
technology appraisal guidance 86)
Web reference for appraisal and other related
documents: http://www.nice.org.uk/guidance/TA209
NHSScotland should note that:
1. No important differences were identified
for this NICE appraisal and NHS Quality Improvement Scotland
advises that the recommendations are as valid for Scotland as for
England and Wales.
2. This guidance updates, but does not change,
recommendation 1.4 of TA86. All other recommendations in TA86 still
stand (http://guidance.nice.org.uk/TA86/Guidance/Recommendation).
3. This MTA assesses the clinical and
cost-effectiveness of imatinib at a dose of 600 or800 mg/day in
people with unresectable and/or metastatic GIST whose disease has
progressed at the lower imatinib dose (400 mg/day). The Scottish
Medicines Consortium (SMC) has previously accepted imatinib for
restricted use at a dose of 400mg/day in this indication (08/02)
but has not assessed the clinical and cost-effectiveness of the
higher dose of imatinib.
4. NHSScotland should take account of the NICE
appraisal and this NHS Quality Improvement Scotland email in its
planning, funding and provision of services to ensure that
recommended drugs or treatments are made available to meet clinical
need.
5. Copies of the NICE appraisal can be
downloaded from http://www.nice.org.uk. Also on the website is a
costing statement that NICE has developed to accompany this
guidance.
Finally, an easy to read summary of the
appraisal, called "understanding NICE guidance" is published on the
NICE website to provide information for patients and the
public.
6. NHS Quality Improvement Scotland advice
represents the evidence-based view of NHS Quality Improvement
Scotland.
7. This advice does not override or replace
the individual responsibility of health professionals to make
appropriate decisions in the circumstances of their individual
patients, in consultation with the patient and/or guardian or
carer.
8. No other publications on the NICE appraisal
will be issued by NHS Quality Improvement Scotland.
9. Hard copies of the NICE appraisals are
available from NHS Quality Improvement Scotland and all NICE
appraisals and NHS Quality Improvement Scotland advice are
available on the NHS Quality Improvement Scotland website
(http://www.nhshealthquality.org/).
If you need further assistance, please contact Eleanor Brownlee in
the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net
).
Published Date: 24 November 2010
